02 November 2022
SightGlass vision outlined results from the Cypress myopia control clinical trial at the American Academy of Optometry annual meeting (San Diego, 27 October).
The company highlighted that SightGlass Vision spectacles with Diffusion Optics Technology reduced both axial length and cycloplegic spherical equivalent progression among six to 10-year-olds compared to a control group.
Data from the Cypress trial showed that there had been no serious adverse events linked to the study during the three-year period.
While the technology was beneficial across different age groups, SightGlass highlighted that slowing myopia progression in children aged six to seven at the beginning of treatment was of particular note.
“There are currently no other interventions with this degree of demonstrated efficacy for six and seven-year-old children,” SightGlass chief executive, Andrew Sedgwick, said.
SightGlass enrolled a subset of younger children to examine a gap in myopia control research and management options.
Sedgwick described the technology as a “first line of defence” for young myopes.
Diffusion Optics Technology lenses use thousands of micro-dots that scatter light to reduce contrast on the retina.
Comments (3)
You must be logged in to join the discussion. Log in
Anonymous03 November 2022
So how much does it reduce progression of myopia?
ReportLike161
Dave C03 November 2022
Poor article
1) The meeting was American Academy of Optometry 2022
2) Please let us know what the results show, or at least embed a link to the publication, otherwise the article is useless.
ReportLike167
Anonymous02 November 2022
“Diffusion Optics Technology lenses use thousands of micro-dots that scatter light to reduce contrast on the retina.”
So, imperfect vision in exchange for a tiny bit less myopia. Is that a win?
ReportLike175